Quantum BioPharma Ltd. Announces Completion of Dosing for Lucid-21-302 Studies

Quantum BioPharma Ltd. has announced the completion of oral dosing in 180-day toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS). These studies are crucial for supporting the Investigational New Drug (IND) application with the US FDA and will inform the design of a Phase 2 trial for Lucid-MS in patients with multiple sclerosis (MS). The company is focused on developing Lucid-MS as a potential first-in-class treatment to prevent disease progression and demyelination in MS. Quantum BioPharma is also involved in other ventures, including an investment in Unbuzzd Wellness Inc. and strategic investments through its subsidiary FSD Strategic Investments Inc. The company has provided forward-looking statements regarding potential outcomes of litigation and future business performance, while also cautioning about inherent risks and uncertainties.